Barchart.com
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Ibio Inc (IBIO)

Ibio Inc (IBIO)
1.1600 x 20 1.2200 x 2
Post-market by (Cboe BZX)
1.2000 -0.0100 (-0.83%) 04/11/25 [NASDAQ]
1.1600 x 20 1.2200 x 2
Post-market 1.1700 -0.0300 (-2.50%) 16:25 ET
News & Headlines for Fri, Apr 11th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
iBio Stock Plummets Despite Positive Data On Weight-Loss Treatment Antibody: Retail Stays Bearish Stocktwits - Mon Apr 7, 12:24PM CDT

However, the company said that the study does not prove statistical significance and only involves a single administration of the antibody.

VXF : 160.66 (+1.55%)
DFAT : 46.78 (+1.01%)
IBIO : 1.2000 (-0.83%)
iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline GlobeNewswire - Mon Apr 7, 6:00AM CDT

IBIO : 1.2000 (-0.83%)
iBio to Begin Trading on the Nasdaq Stock Exchange GlobeNewswire - Wed Feb 19, 3:05PM CST

IBIO : 1.2000 (-0.83%)
iBio Reports Fiscal Second Quarter 2025 Financial Results GlobeNewswire - Mon Feb 10, 3:05PM CST

IBIO : 1.2000 (-0.83%)
iBio Announces New Investments from Board Members and Officers GlobeNewswire - Mon Jan 13, 6:00AM CST

IBIO : 1.2000 (-0.83%)
iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio GlobeNewswire - Tue Jan 7, 6:00AM CST

IBIO : 1.2000 (-0.83%)
iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio GlobeNewswire - Thu Jan 2, 6:00AM CST

IBIO : 1.2000 (-0.83%)
iBio Strengthens Board with Appointment of Two New Independent Directors GlobeNewswire - Mon Nov 25, 2024

IBIO : 1.2000 (-0.83%)
iBio Reports Fiscal First Quarter 2025 Financial Results GlobeNewswire - Tue Nov 12, 2024

IBIO : 1.2000 (-0.83%)
Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching Stocktwits - Fri Nov 8, 2024

Less stringent requirements in pharmaceuticals and biotechnology could help biotechs by prompting accelerated drug approvals.

SRNE : 0.0010 (+11.11%)
TNXP : 16.88 (-2.43%)
IBB : 116.96 (+3.38%)
JAGX : 5.57 (+8.79%)
NVAX : 5.86 (+7.92%)
INO : 1.6100 (+1.90%)
GILD : 103.63 (+2.20%)
MRNA : 26.20 (+6.94%)
VXRT : 0.3600 (+14.50%)
IBIO : 1.2000 (-0.83%)
XBI : 74.33 (+3.80%)
PFE : 21.91 (+1.48%)

Barchart Exclusives

This Nvidia-Backed AI Stock Is Shrugging Off Market Pain Thanks to the FDA. Should You Buy Shares Now? Barchart - 10 minutes ago
Recursion Pharmaceuticals stock rallied as FDA announces plans of using AI for drug testing. Is it too late to invest in RXRX shares? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
UTC
Reserve Your Spot